Citadel Advisors’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-16,260
Closed -$48.4K 15750
2023
Q3
$48.4K Sell
16,260
-16,925
-51% -$39.4K ﹤0.01% 11789
2023
Q2
$80.6K Sell
33,185
-61,261
-65% -$101K ﹤0.01% 11242
2023
Q1
$161K Buy
+94,446
New +$214K ﹤0.01% 10527
2021
Q4
Sell
-1,286
Closed -$59K 15278
2021
Q3
$59K Buy
1,286
+754
+142% +$37K ﹤0.01% 13280
2021
Q2
$32K Buy
532
+21
+4% +$1.48K ﹤0.01% 13472
2021
Q1
$52K Buy
+511
New +$44K ﹤0.01% 12887
2019
Q4
Sell
-25
Closed -$5K 9993
2019
Q3
$5K Buy
25
+3
+14% +$719 ﹤0.01% 9072
2019
Q2
$8K Sell
22
-6
-21% -$4.68K ﹤0.01% 9056
2019
Q1
$36K Buy
+28
New +$45.4K ﹤0.01% 8948
2018
Q4
Sell
-20
Closed -$57K 9985
2018
Q3
$57K Sell
20
-2
-9% -$5.78K ﹤0.01% 8779
2018
Q2
$71K Buy
22
+12
+120% +$40.5K ﹤0.01% 8363
2018
Q1
$34K Buy
+10
New +$29.6K ﹤0.01% 8025
2017
Q4
Sell
-2
Closed -$8K 8597
2017
Q3
$8K Buy
2
+1
+100% +$5.14K ﹤0.01% 7446
2017
Q2
$9K Sell
1
-1
-50% -$8.71K ﹤0.01% 7378
2017
Q1
$15K Buy
+2
New +$13.8K ﹤0.01% 7317
2016
Q3
Sell
-1
Closed -$9K 7944
2016
Q2
$9K Hold
1
﹤0.01% 6733
2016
Q1
$16K Hold
1
﹤0.01% 6536
2015
Q4
$19K Buy
+1
New +$18.9K ﹤0.01% 7980

Citadel Advisors's TMBR Position: Q4 2023 in Review

Citadel Advisors sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2023, closing a stake of 16,260 shares — an estimated $48.4K sold.

Citadel Advisors first reported a position in TMBR in Q4 2015 and held it in 18 quarters. The position peaked at $161K in Q1 2023. 0 funds tracked by Wall St. Rank hold TMBR as of Q4 2023.

  • Citadel Advisors reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 16,260 Timber Pharmaceuticals, Inc. shares in Q4 2023, an estimated $48.4K.
  • Citadel Advisors first reported a position in Timber Pharmaceuticals, Inc. in Q4 2015 and held it in 18 quarters.
  • Citadel Advisors's Timber Pharmaceuticals, Inc. position peaked at $161K in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.